Pharmacological Effects of HMG CoA Reductase Inhibitors Other Than Lipoprotein Modulation
- 1 February 1999
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 39 (2) , 111-118
- https://doi.org/10.1177/00912709922007642
Abstract
The HMG CoA reductase inhibitors reduce levels of low‐density lipoproteins, raise high‐density lipoproteins, and lower triglycerides. However, there are other pharmacological effects derived from HMG...Keywords
This publication has 59 references indexed in Scilit:
- Endothelial vasodilator dysfunction: Pathogenetic link to myocardial ischaemia or epiphenomenon?The Lancet, 1996
- Reduction of Serum Cholesterol Levels Alters Lesional Composition of Atherosclerotic PlaquesArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Postischemic Blood Flow Response in Hypercholesterolemic PatientsHypertension, 1995
- Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery diseaseThe American Journal of Cardiology, 1995
- Pathogenesis of atherosclerosisand the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitorsThe American Journal of Cardiology, 1995
- Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemiaThe American Journal of Cardiology, 1993
- A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemiaThe American Journal of Cardiology, 1993
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Lovastatin Therapy in Hypercholesterolemia: Effect on Fibrinogen, Hemorrheologic Parameters, Platelet Activity, and Red Blood Cell MorphologyThe Journal of Clinical Pharmacology, 1991
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985